• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

构建包含 2004 年 WHO/ISUP 分级的列线图预测模型用于预测非肌层浸润性膀胱尿路上皮肿瘤患者的预后。

Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder.

机构信息

Department of Pathology, Taipei Veterans General Hospital & National Yang-Ming University, Taipei, Taiwan.

出版信息

J Clin Pathol. 2010 Oct;63(10):910-5. doi: 10.1136/jcp.2010.079764.

DOI:10.1136/jcp.2010.079764
PMID:20876324
Abstract

AIM

To construct a prognostic model for recurrence-free survival (RFS), progression-free survival (PFS) and cancer-specific survival (CSS) for patients who have undergone transurethral resection of non-muscle-invasive (pTa/pT1) urinary bladder urothelial tumours.

METHODS

1366 patients who had undergone transurethral resection of primary non-muscle-invasive urothelial tumours (pTa, 891 patients; pT1, 475 patients) confined to the bladder were retrospectively studied. Tumours were classified according to the 2004 WHO/International Society of Urologic Pathology grading system. Kaplan-Meier and stepwise Cox regression models were applied, and 200 bootstrap resamples were used to generate survival estimates and 95% CIs. A nomogram was developed that incorporated significant variables predicting survival.

RESULTS

RFS, PFS and CSS probabilities for non-muscle-invasive bladder urothelial tumours were calculated. Incorporating salient prognostic factors (tumour grade, pT stage, patient age, status of intravesical instillation), the model satisfactorily predicted PFS (concordance index=0.79) and CSS (concordance index=0.87).

CONCLUSIONS

Robust nomograms were created to predict PFS and CSS. These data provide an overall perspective of disease outcomes which may aid in developing individualised follow-up programmes.

摘要

目的

为接受经尿道非肌肉浸润性(pTa/pT1)膀胱尿路上皮肿瘤切除术的患者构建无复发生存(RFS)、无进展生存(PFS)和癌症特异性生存(CSS)的预后模型。

方法

回顾性研究了 1366 例接受经尿道切除原发性非肌肉浸润性尿路上皮肿瘤(pTa,891 例;pT1,475 例)的患者。肿瘤根据 2004 年世界卫生组织/国际泌尿病理学会分级系统进行分类。应用 Kaplan-Meier 和逐步 Cox 回归模型,并使用 200 次 bootstrap 重采样生成生存估计值和 95%CI。开发了一个包含预测生存的显著变量的列线图。

结果

计算了非肌肉浸润性膀胱尿路上皮肿瘤的 RFS、PFS 和 CSS 概率。纳入显著的预后因素(肿瘤分级、pT 分期、患者年龄、膀胱内灌注状态)后,该模型可满意地预测 PFS(一致性指数=0.79)和 CSS(一致性指数=0.87)。

结论

创建了稳健的列线图来预测 PFS 和 CSS。这些数据提供了疾病结局的整体视角,可能有助于制定个体化的随访计划。

相似文献

1
Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder.构建包含 2004 年 WHO/ISUP 分级的列线图预测模型用于预测非肌层浸润性膀胱尿路上皮肿瘤患者的预后。
J Clin Pathol. 2010 Oct;63(10):910-5. doi: 10.1136/jcp.2010.079764.
2
Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.2004 年世卫组织/国际泌尿病理学会分类对预测非肌肉浸润性膀胱尿路上皮肿瘤的复发、进展和癌症特异性死亡率的预后意义:1515 例临床病理研究。
Am J Clin Pathol. 2010 May;133(5):788-95. doi: 10.1309/AJCP12MRVVHTCKEJ.
3
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.复发性高危浅表性膀胱肿瘤患者根治性膀胱切除术的最佳时机。
BJU Int. 2004 Dec;94(9):1258-62. doi: 10.1111/j.1464-410X.2004.05228.x.
4
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果:日本泌尿外科学会1999 - 2001年报告
Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.
5
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.膀胱非肌层浸润性尿路上皮细胞癌患者中Survivin的表达
Urology. 2007 Sep;70(3):482-6. doi: 10.1016/j.urology.2007.05.009.
6
Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset?当前世界卫生组织的分类法能否更好地预测早期或常规发病的非侵袭性膀胱癌患者的预后?
BJU Int. 2008 Jul;102(2):194-7. doi: 10.1111/j.1464-410X.2008.07538.x. Epub 2008 Jul 1.
7
Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.高危浅表性膀胱癌的再次经尿道切除术可改善对卡介苗治疗的初始反应。
J Urol. 2005 Dec;174(6):2134-7. doi: 10.1097/01.ju.0000181799.81119.fc.
8
Outcome of very large superficial bladder tumours: a 10-year experience.超大型浅表性膀胱肿瘤的治疗结果:十年经验
Scand J Urol Nephrol. 2008;42(3):243-8. doi: 10.1080/00365590701832759.
9
[BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].卡介苗与光动力疗法(PDT)治疗非肌层浸润性膀胱癌——一项多中心临床III期研究
Aktuelle Urol. 2009 Mar;40(2):91-9. doi: 10.1055/s-0028-1098741. Epub 2009 Feb 12.
10
[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Prog Urol. 1998 Apr;8(2):206-10.

引用本文的文献

1
Non-invasive low-grade papillary urothelial carcinoma with whorled features: a report of two cases.具有漩涡状特征的非侵袭性低级别乳头状尿路上皮癌:两例报告
Int J Clin Exp Pathol. 2025 Feb 15;18(2):89-95. doi: 10.62347/DFQO7724. eCollection 2025.
2
News in the classification of WHO 2022 bladder tumors.2022 年世卫组织膀胱癌分类的新进展。
Pathologica. 2022 Feb;115(1):32-40. doi: 10.32074/1591-951X-838. Epub 2023 Jan 25.
3
Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score.
基于术前控制营养状态评分的原发性非肌层浸润性膀胱癌患者无复发生存预测新列线图的开发
Cancer Manag Res. 2021 Aug 16;13:6473-6487. doi: 10.2147/CMAR.S323844. eCollection 2021.
4
Prediction tools in non-muscle invasive bladder cancer.非肌层浸润性膀胱癌的预测工具
Transl Androl Urol. 2019 Feb;8(1):39-45. doi: 10.21037/tau.2019.01.15.
5
Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.新型列线图预测原发性非肌肉浸润性膀胱癌的复发和进展:与欧洲癌症研究与治疗组织评分系统相比预测效能的验证。
World J Urol. 2019 Sep;37(9):1867-1877. doi: 10.1007/s00345-018-2581-3. Epub 2018 Dec 10.
6
Non-muscle invasive bladder cancer risk stratification.非肌层浸润性膀胱癌风险分层
Indian J Urol. 2015 Oct-Dec;31(4):289-96. doi: 10.4103/0970-1591.166445.
7
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation.中危非肌层浸润性膀胱癌患者膀胱内化疗后复发概率的预测模型,包括外部验证
World J Urol. 2016 Feb;34(2):173-80. doi: 10.1007/s00345-015-1598-0. Epub 2015 May 30.
8
Impact of 2004 ISUP/WHO classification on bladder cancer grading.2004年国际泌尿病理学会/世界卫生组织分类对膀胱癌分级的影响。
World J Urol. 2015 Dec;33(12):1929-36. doi: 10.1007/s00345-015-1548-x. Epub 2015 Apr 2.
9
[Non-invasive and invasive urothelial tumours: special challenges in uropathological diagnostics].[非侵袭性和侵袭性尿路上皮肿瘤:泌尿病理诊断中的特殊挑战]
Urologe A. 2013 Jul;52(7):949-57. doi: 10.1007/s00120-013-3225-2.